Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Early Discovery, Family Understanding Important to Treat OCD: GSK Seminar
February 20, 2006
- BUSINESS NEWS IN BRIEF
February 20, 2006
- JASDI Forum on Drug Information Needed by Patients
February 20, 2006
- 188th PMAT Seminar
February 20, 2006
- MEDICAL DEVICE NEWS IN BRIEF
February 20, 2006
- Present New Invoice Prices within 3 Days after New NHI Price Announcement: FJPWA
February 20, 2006
- HIV Drug Resistance Measurement Method Developed
February 20, 2006
- Managerial-level Workers at Pfizer Japan Form New Labor Union
February 20, 2006
- Fuji Biomedix Develops Kit to Diagnose Malignancy of Colon Cancer
February 20, 2006
- Aiming at \10 Bil. Sales with Seibule: Sanwa Kagaku
February 20, 2006
- ＜OPINION＞ Romancing the Right Remuneration
February 20, 2006
- R&D NEWS IN BRIEF
February 20, 2006
- Dr M. Angell's Book Publication Seminar
February 20, 2006
- Univ. Hospitals Should Improve Infrastructure for TR: Prof. Fukushima
February 20, 2006
- APDD to Promote Clinical Trials
February 20, 2006
- ＜Symposium＞ "Tamiflu Should Not Be Used": Medwatcher Japan
February 20, 2006
- REGULATORY NEWS IN BRIEF
February 20, 2006
- Chuikyo's Reform to Take Place in March 2007
February 20, 2006
- Bill Payers, Care Providers Clash on Mandatory Receipts
February 20, 2006
- Chugai to Start Big Leap Forward in 2006
February 20, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…